Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabichromene as an Adjunct to Rheumatoid Arthritis Treatment
NCT07087938Phase 2Withdrawn
- Start
- Jul 2028
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabichromene in rheumatoid arthritis (RA). Planned start Jul 2028; status: withdrawn.
02
Drugs
cannabichromene
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07087938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07087938.